Edwards Lifesciences Corporation $EW Shares Sold by Ninety One North America Inc.

Key Points

• Ninety One North America reduced its Edwards Lifesciences stake by 5.6% in the third quarter, selling 34,328 shares and retaining 582,170 shares valued at approximately $50.3 million.
• Institutional investors and hedge funds own 79.46% of Edwards Lifesciences, while company insiders sold 5,045 shares worth about $451,596 over the past 90 days.
• Edwards reported quarterly earnings and revenue above analyst expectations, with revenue up 13.6% year over year. Analysts maintain a “Moderate Buy” consensus rating and an average price target of $100.27 versus the stock’s recent price of $86.56.

Ninety One North America Inc. decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 582,170 shares of the medical research company's stock after selling 34,328 shares during the period. Edwards Lifesciences accounts for 2.5% of Ninety One North America Inc.'s portfolio, making the stock its 11th largest position. Ninety One North America Inc. owned 0.10% of Edwards Lifesciences worth $50,253,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $5,318,092,000. Varma Mutual Pension Insurance Co acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $11,168,000. Conway Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the second quarter worth about $954,000. Commerce Bank bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at about $3,121,000. Finally, Bank of America Corp DE acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $605,397,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 544 shares of the company's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Annette Brüls sold 2,644 shares of the company's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.11 during trading on Thursday, reaching $86.56. 1,261,235 shares of the company's stock were exchanged, compared to its average volume of 4,490,733. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.84 billion, a PE ratio of 49.73, a PEG ratio of 2.23 and a beta of 0.87. Edwards Lifesciences Corporation has a twelve month low of $72.42 and a twelve month high of $96.29. The firm's fifty day moving average price is $88.53 and its 200-day moving average price is $86.27.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same quarter in the prior year, the business earned $0.67 EPS. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3.00 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on EW shares. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, September 26th. Citigroup reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Monday, October 5th. Finally, TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.